Cedar Brook Financial Partners’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-39,668
| Closed | -$180K | – | 31 |
|
|
2024
Q1 | $180K | Hold |
39,668
| – | – | 0.04% | 425 |
|
|
2023
Q4 | $216K | Buy |
39,668
+9,418
| +31% | +$51.3K | 0.05% | 369 |
|
|
2023
Q3 | $139K | Buy |
30,250
+5,000
| +20% | +$23K | 0.04% | 367 |
|
|
2023
Q2 | $163K | Buy |
25,250
+1,285
| +5% | +$8.3K | 0.04% | 391 |
|
|
2023
Q1 | $181K | Hold |
23,965
| – | – | 0.05% | 372 |
|
|
2022
Q4 | $243K | Buy |
23,965
+2,000
| +9% | +$20.3K | 0.07% | 305 |
|
|
2022
Q3 | $217K | Buy |
21,965
+1,000
| +5% | +$9.89K | 0.07% | 305 |
|
|
2022
Q2 | $223K | Buy |
20,965
+4,000
| +24% | +$42.5K | 0.07% | 303 |
|
|
2022
Q1 | $165K | Buy |
16,965
+5,250
| +45% | +$51.1K | 0.04% | 367 |
|
|
2021
Q4 | $168K | Buy |
+11,715
| New | +$168K | 0.04% | 369 |
|